Description:
Baseline Lymphoma Disease Activity and Assessment (LAA) Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=11409201-BB50-09A2-E044-0003BA3F9857
Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=11409201-BB50-09A2-E044-0003BA3F9857Keywords:
Versions (4)
- 8/26/12 8/26/12 -
- 2/3/15 2/3/15 - Martin Dugas
- 4/13/21 4/13/21 - Dr. rer. medic Philipp Neuhaus
- 9/20/21 9/20/21 -
Uploaded on:
August 26, 2012
DOI:
To request one please log in.License :
Creative Commons BY-NC 3.0 LegacyModel comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
AIDS-Related Lymphoma NCT00310128 Treatment - Baseline Lymphoma Disease Activity and Assessment (LAA) - 2474331v1.0
No Instruction available.
- StudyEvent: Baseline Lymphoma Disease Activity and Assessment (LAA)